CXLUSA is the world’s largest research study group that has researched and developed minimally-invasive treatment of keratoconus and post-LASIK ectasia using epithelium-on corneal crosslinking (CXL).

Apr 6, 2018 · If you are in the area and have KC, I highly recommend her! She told me that they were a part of an FDA trial called CXLUSA and that she performed epi-on procedures with excellent success rates. She informed me that CXLUSA has been doing epi-on for years now but doesn’t have FDA approval.

These ophthalmologists have formed a group called CXLUSA, which has evolved into an advocacy community for the epi-on procedure. Here, Roy Rubenfeld, MD, a spokesperson for the group, answers relevant questions about CXLUSA and its work.

Jan 9, 2018 · When it comes to corneal cross-linking (CXL), every single one of us is currently in the “epi-off” camp. Why? Because corneal ectasias like keratoconus need to be dealt with effectively – and, if CXL is the right approach to take for an ectatic cornea, then performing epi-off (rather than epi-on) CXL is almost always the right choice.

CXLUSA, LLC. PAGE 4 PROTOCOL CXL-005, REV. 04.3 05 MAY, 2017 Study Procedures (cont’d) epithelial debridement, and promoting faster vision recovery to baseline CDVA. D. Apply a CXLO round loading sponge to the surface of the cornea to serve as a reservoir for CXLO Corneal Strengthening Solution.

CXLUSA is the world’s largest research study group that has researched and developed minimally-invasive treatment of keratoconus and post-LASIK ectasia using epithelium-on corneal crosslinking. CXLUSA has developed and shared the latest research from keratoconus clinical trials and epithelium-on CXL since 2009.

Read the latest publications about advances in corneal collagen crosslinking (CXL) and articles by CXLUSA participating practices, physicians, and other world experts.

The findings of this study indicate that epi-on CXL using the CXLUSA protocol halted the progression of ectatic disease, improving K max, visual acuity, higher-order aberrations, and coma and avoiding the complications of epithelial removal—an effect that is not lost between 12 and 24 months after treatment. The question now is this: Will the ...

orneal collagen cross-linking (CXL) for the treatment of keratoco-nus and ectasia has been approved throughout the European Union since 2006 but has yet to receive approval in the U.S.

CXLUSA • Evaluation of Epi-on vs. Epi-off • Treatment of the following conditions: • Keratoconus • Pellucid Marginal Degeneration • Post-refractive ectasia • Post-RK Visual Fluctuation CXL IN CXLUSA also allows for CXL to be used in conjunction with: • Intacs • Conductive Keratoplasty • PRK • Modification of Epi-on Technique